These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 11557471)

  • 21. TARGETed surveillance: susceptibility of Streptococcus pneumoniae isolated from community-acquired respiratory tract infections in 2003 to fluoroquinolones and other agents.
    Morrissey I; Colclough A; Northwood J
    Int J Antimicrob Agents; 2007 Oct; 30(4):345-51. PubMed ID: 17643269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication.
    Lister PD
    Antimicrob Agents Chemother; 2002 Jan; 46(1):69-74. PubMed ID: 11751113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance.
    Ferrara AM
    Infection; 2005 Jun; 33(3):106-14. PubMed ID: 15940410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones.
    Wispelwey B
    Clin Infect Dis; 2005 Jul; 41 Suppl 2():S127-35. PubMed ID: 15942879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae.
    Owens RC; Bhavnani SM; Ambrose PG
    Diagn Microbiol Infect Dis; 2005 Jan; 51(1):45-9. PubMed ID: 15629228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Broth microdilution and E-test for determining fluoroquinolone activity against Streptococcus pneumoniae.
    Kays MB; Graff MA
    Ann Pharmacother; 2002 Mar; 36(3):416-22. PubMed ID: 11895052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Guide to selection of fluoroquinolones in patients with lower respiratory tract infections.
    Shams WE; Evans ME
    Drugs; 2005; 65(7):949-91. PubMed ID: 15892589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease.
    Conte JE; Golden JA; McIver M; Little E; Zurlinden E
    Int J Antimicrob Agents; 2007 Nov; 30(5):422-7. PubMed ID: 17716873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Coyle EA; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1654-9. PubMed ID: 11353608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus pneumoniae.
    Appelbaum PC
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S29-34. PubMed ID: 10984325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia.
    Bhavnani SM; Forrest A; Hammel JP; Drusano GL; Rubino CM; Ambrose PG
    Diagn Microbiol Infect Dis; 2008 Sep; 62(1):99-101. PubMed ID: 18583085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and pharmacodynamics of gatifloxacin in children with recurrent otitis media: application of sparse sampling in clinical development.
    Rubino CM; Ambrose P; Cirincione B; Arguedas A; Sher L; Lopez E; Sáez-Llorens X; Grasela DM
    Diagn Microbiol Infect Dis; 2007 Sep; 59(1):67-74. PubMed ID: 17875453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Moxifloxacin in lower respiratory tract infections: in silico simulation of different bacterial resistance and drug exposure scenarios.
    Salem AH; Noreddin AM
    J Chemother; 2014 Apr; 26(2):80-5. PubMed ID: 24090676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.
    Firsov AA; Alferova IV; Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2005 May; 25(5):409-13. PubMed ID: 15848296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety.
    Bhavnani SM; Andes DR
    Pharmacotherapy; 2005 May; 25(5):717-40. PubMed ID: 15899734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.
    Preston SL; Drusano GL; Berman AL; Fowler CL; Chow AT; Dornseif B; Reichl V; Natarajan J; Corrado M
    JAMA; 1998 Jan; 279(2):125-9. PubMed ID: 9440662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluoroquinolone susceptibility, resistance, and pharmacodynamics versus clinical isolates of Streptococcus pneumoniae from Indiana.
    Kays MB; Denys GA
    Diagn Microbiol Infect Dis; 2001 Aug; 40(4):193-8. PubMed ID: 11576793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections.
    Zhanel GG; Noreddin AM
    Curr Opin Pharmacol; 2001 Oct; 1(5):459-63. PubMed ID: 11764770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.
    Nightingale CH
    Pharmacotherapy; 2000 Mar; 20(3):245-56. PubMed ID: 10730681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model.
    MacGowan AP; Rogers CA; Holt HA; Bowker KE
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1088-95. PubMed ID: 12604546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.